Protein Aggregation - Part B
- 1st Edition, Volume 146 - July 4, 2025
- Latest edition
- Editor: Rossen Donev
- Language: English
Protein Aggregation - Part B, provides valuable insights into the factors driving protein aggregation, the impact on cellular function, and the role in various diseases, offeri… Read more
Protein Aggregation - Part B, provides valuable insights into the factors driving protein aggregation, the impact on cellular function, and the role in various diseases, offering a comprehensive overview for researchers and professionals in the field of biomedicine and biochemistry.
- Provides the latest information on cancer research
- Offers outstanding and original reviews on a range of cancer research topics
- Serves as an indispensable reference for researchers and students alike
Students, professors, and professionals, Researchers and clinicians
1. Proteostasis Imbalance: Unravelling Protein Aggregation in Neurodegenerative Diseases and Emerging Therapeutic Strategies
Selvaraj Chandrabose Sr., Periyasamy Vijayalakshmi, Elango Elakkiya and Senthilkumar Dhivyashri
2. Alpha-synuclein aggregation in Parkinson disease
Edeildo Ferreira da Silva-Júnior
3. Tau protein aggregation: A therapeutic target for neurodegenerative disease
Vijay Kumar Prajapati
4. Lipids modulates Tau protein aggregation
Subashchandrabose Chinnathambi and Sreeramkumar Selvakumar
5. Heat shock proteins regulates Tau protein aggregation in AD
Subashchandrabose Chinnathambi
6. The aggregation propensity of Amyloid beta and Tau in Alzheimer's disease
Subashchandrabose Chinnathambi, Murugappan Kumurappan, Madhura Chandrashekar and Sneha Malik
7. The cross-talk between ApoE and Tau protein in Alzheimer's disease
Subashchandrabose Chinnathambi, Madhura Chandrashekar and Murugappan Kumurappan
8. Modifiable Chemical Risk Factors for Tau protein in Alzheimer's Disease
Subashchandrabose Chinnathambi, Sneha Malik, Murugappan Kumurappan and Madhura Chandrashekar
Selvaraj Chandrabose Sr., Periyasamy Vijayalakshmi, Elango Elakkiya and Senthilkumar Dhivyashri
2. Alpha-synuclein aggregation in Parkinson disease
Edeildo Ferreira da Silva-Júnior
3. Tau protein aggregation: A therapeutic target for neurodegenerative disease
Vijay Kumar Prajapati
4. Lipids modulates Tau protein aggregation
Subashchandrabose Chinnathambi and Sreeramkumar Selvakumar
5. Heat shock proteins regulates Tau protein aggregation in AD
Subashchandrabose Chinnathambi
6. The aggregation propensity of Amyloid beta and Tau in Alzheimer's disease
Subashchandrabose Chinnathambi, Murugappan Kumurappan, Madhura Chandrashekar and Sneha Malik
7. The cross-talk between ApoE and Tau protein in Alzheimer's disease
Subashchandrabose Chinnathambi, Madhura Chandrashekar and Murugappan Kumurappan
8. Modifiable Chemical Risk Factors for Tau protein in Alzheimer's Disease
Subashchandrabose Chinnathambi, Sneha Malik, Murugappan Kumurappan and Madhura Chandrashekar
- Edition: 1
- Latest edition
- Volume: 146
- Published: July 4, 2025
- Language: English
RD
Rossen Donev
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.
Affiliations and expertise
Head of Research, MicroPharm Limited, UKRead Protein Aggregation - Part B on ScienceDirect